ARCHIVES

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

This article is from The Cancer Letter archive.

Vol. 26 No. 12 | December 26, 2003

Download PDF Visit The Full Archive

Related Articles

FDA Committee nixes Combination Guidelines, Okays New NDA Policy

January 21, 1977

Et2’s Referral Guidelines

July 23, 1993

Litton Wins FCRF Research Contract, Harland Land Animal Protections

September 17, 1982

Rhoads Presses For Greater Emphasis On Etiology In DNCP; Workshops Develop New Research Leads

July 16, 1976

White House Budget asks $1.101 Billion For NCI In FY 1985; R01-P01 Pool Goes Up By 5.5 Percent

February 10, 1984

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

October 3, 2014